{"entity":{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of ETX-19477 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by 858 Therapeutics, Inc., now recruiting.","summary":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06395519 by 858 Therapeutics, Inc., with 120 participants planned, started 2024-05-13 and due to reach its primary completion in 2026-12. Interventions recorded: ETX-19477.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06395519","url":"https://clinicaltrials.gov/study/NCT06395519"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","prostate","endometrial","colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06395519","phase":"1/2","setting":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","sponsor":"858 Therapeutics, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct06395519/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}